市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Erasca, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-0.8
| 分析师共识 | -1.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.75 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.69% |
| 机构持股比例 | 84.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Jun 2025 | 14,502,004 |
| Arch Venture Management, Llc | 30 Jun 2025 | 11,055,554 |
| Siren, L.L.C. | 30 Jun 2025 | 8,757,249 |
| Vivo Capital, Llc | 30 Jun 2025 | 6,756,756 |
| 5Am Venture Management, Llc | 30 Jun 2025 | 5,405,404 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 4.00 (Stifel, 58.10%) | 购买 |
| 中 | 2.00 (-20.95%) | |
| 低 | 1.00 (B of A Securities, -60.47%) | 卖出 |
| 平均值 | 2.33 (-7.91%) | |
| 总计 | 1 购买, 1 保留, 1 卖出 | |
| 平均价格@调整类型 | 1.83 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 16 Oct 2025 | 4.00 (58.10%) | 购买 | 2.53 |
| B of A Securities | 03 Sep 2025 | 1.00 (-60.47%) | 卖出 | 1.43 |
| Morgan Stanley | 18 Aug 2025 | 2.00 (-20.95%) | 保留 | 1.53 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 02 Sep 2025 | 公告 | Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 12 Aug 2025 | 公告 | Erasca Reports Second Quarter 2025 Business Updates and Financial Results |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合